Routine Care

PreclinicalSmall molecule

UUniversity of California, Los Angeles

Routine Care is one of 32 small molecule programs targeting Peripheral Neuropathy. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Peripheral NeuropathyActive, not recruiting

Peripheral NeuropathyPreclinical

Active, not recruiting

Competition

Competitive Landscape

38 competitors in Peripheral Neuropathy

#DrugCompanyPhaseTrials

Cymbalta

Jazz Pharmaceuticals

Approved

9 2

Lyrica

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

24 3

Savella

AbbVie

Approved

—4

Neurontin

VViatris Specialty LLC

Approved

3 5

Accupril

Pfizer

Approved

1 6

Velcade

SShilpa Grover, MD, MPH

Approved

1 7

Prilosec

DDexcel Pharma Technologies Ltd.

Adrucil

Cymbalta

2 10

Eloxatin

Teva

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Type 2 Diabetes1 trial

INSPIRE Diabetes Study: Basal Bolus Insulin as Primary Treatment of Type 2 Diabetes

Completed·OOhio University·Phase 4·NCT01087567·23 enrolled

EGFR1 trial

A Study to Investigate Nicotinic Acid on VEGFR Inhibitor-Associated Hand-Foot Skin Reactions

Unknown status·FFirst People's Hospital of Hangzhou·Phase 2·NCT04242927·36 enrolled

Arrhythmia1 trial

Cardiac Sympathetic Denervation for Prevention of Ventricular Tachyarrhythmias

Unknown status·UUniversity of California, Los Angeles·Phase 3·NCT01013714·40 enrolled

Peripheral Neuropathy1 trial

ACUpuncture in Diabetic Peripheral Neuropathy

Completed·BBenno Brinkhaus·N/A·NCT03755960·62 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Routine Care. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Routine Care compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Routine Care. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of California, Los Angeles company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: UUniversity of California, Los Angeles

Routine Care

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Type 2 Diabetes1 trial

EGFR1 trial

Arrhythmia1 trial

Peripheral Neuropathy1 trial

References

Drug Info

Quick Facts

Related News